Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul 2;15(1):22867.
doi: 10.1038/s41598-025-00062-x.

Phase II study of transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced perihilar cholangiocarcinoma

Hao Li  1 , Pengfei Chen  1 , Mengfan Zhang  1 , Zhengfeng Wang  2 , Yanbang Lian  3 , Baohong Wen  4 , Jianzhuang Ren  1 , Xinwei Han  1 , Bingjie Li  5 , Xuhua Duan  6
Affiliations
Clinical Trial

Phase II study of transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced perihilar cholangiocarcinoma

Hao Li et al. Sci Rep. .

Abstract

To confirm transcatheter arterial chemoembolization (TACE) combined with apatinib for advanced perihilar cholangiocarcinoma (PCC) is effective and safe. A comprehensive treatment plan involving TACE combined with targeted therapy was implemented for the patients with pathologically diagnosed advanced PCC, where TACE was performed every 4-6 weeks to deliver albumin paclitaxel and gemcitabine for a maximum of six times. Oral apatinib was administered in between TACE cycles. The main endpoint of this study was the objective response rate (ORR), and the secondary endpoints were progression free survival (PFS), overall survival (OS), and adverse events. Kaplan-Meier method was used to assess survival risk factors. From November 2019 to October 2020, a total of 41 patients were enrolled with perihilar cholangiocarcinoma who were pathologically diagnosed. All underwent TACE treatment and received at least two treatment cycles. As of October 2022, the median follow-up period of this study was 28.3 months, the ORR of this study reached 56.1% (95% CI 39.7-71.5%); DCR reached 90.2% (95% CI 76.9-97.3%), and the median PFS was 9.7 months (95% CI 7.6-11.8 months), the median OS was 16.5 months (95% CI 13.6-19.3 months). The treatment-related adverse events (AEs) in this study were mild, mainly Grade 1 or 2. Among the most common AEs were bone marrow suppression and hand-foot syndrome, while no patient had Grade 4 AE. Comprehensive treatment combining TACE with apatinib for advanced PCC had favorable therapeutic effects, and no major safety issue was observed in the patients enrolled.

Keywords: Apatinib; Efficacy; Keywords; Perihilar cholangiocarcinoma; Safety; Transcatheter arterial chemoembolization.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Ethics approval: This single-arm single-center phase II clinical trial was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. Informed consent: All patients provided written informed consent.

Figures

Fig. 1
Fig. 1
Patient enrollment and disposition.
Fig. 2
Fig. 2
Change in tumor size from baseline to best response among 41 patients (A) and objective response by time on treatment (B).
Fig. 3
Fig. 3
Kaplan-Meier survival curve of progression free survival.
Fig. 4
Fig. 4
Kaplan–Meier survival curve of overall survival.
Fig. 5
Fig. 5
Graphical abstract image.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. BLECHACZ, B. et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat. Reviews Gastroenterol. Hepatol.8(9), 512–522 (2011). - PMC - PubMed
    1. DEOLIVEIRA M L et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg.245(5), 755–762 (2007). - PMC - PubMed
    1. MALKA, D. & CERVERA, P. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial. Lancet Oncol.15(8), 819–828 (2014). - PMC - PubMed
    1. VALLE, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med.362(14), 1273–1281 (2010). - PubMed
    1. CATALANO P J, S. A. H. A. I. V. et al. Nab-Paclitaxel and gemcitabine as First-line treatment of advanced or metastatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol.4(12), 1707–1712 (2018). - PMC - PubMed

Publication types

MeSH terms